Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid
Executive Summary
Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan
You may also be interested in...
Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says
Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said
From The Quarterly Conference Calls
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...
Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says
Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said